 - Received within 4 weeks of Visit 1 or planning to take during participation in the clinical study: any doses of a controlled-release CR LD apart from a single daily bedtime dose or any doses of Rytary, additional CD eg, Lodosyn or benserazide eg, Serazide, or catechol-O-methyl transferase inhibitors entacapone or tolcapone or medications containing these inhibitors Stalevo. Received within 4 weeks of Visit 1 or planning to take during participation in the clinical study: nonselective monoamine oxidase MAO inhibitors, apomorphine, or dopaminergic blocking agents including antiemetics. 